abstract |
AT1-receptor antagonists and particularly the compound (S)-N-(1-carboxy-2-methylprop-1-yl)-N--pentanoyl-N-[2' (1H-tetrazol-5-yl)biphenyl--4-yl-methyl]amine (valsartan) of formula (I) or a salt thereof, in particular a pharmaceutically acceptable salt thereof, can be used for treating (acute and chronic) postischemic renal failure and for protecting the ischemic kidney. |